Posts Tagged ‘company’

Israeli company pharmaceutical manufacturers

Wednesday, September 1st, 2010

Over the past eight years, sales in the global pharmaceutical markethave more than doubled. The United States is still in the lead, reaching the highest per-capita sales in the market as well. It is also the only major industrial country where the provision of medical services and insurance is not unified by a central national strategy.  U.S. market growth in 2010 is now expected to be 3-5 percent. While payers seek to limit price increases and boost the use of lower-cost generics, pharmaceutical manufacturers are expected to maintain their pricing practices, competing on the basis of clinical evidence and value.

Around 85.0% of the USA’s pharmaceutical requirements are domestically manufactured. A number of companies have made significant cutbacks, making reductions to sales forces. There have been a number of plant closures and scaling back of investment plans. There is an increasing interest in moving into the biologic field for companies traditionally reliant on chemical drugs. This is seen as more profitable as it has greater scope for the development of innovative products and is less susceptible to generic competition. With their acquisitions in 2009, Pfizer and Merck have diversified and enter the biologic sector, whilst Roche is specialising in biologics and diagnostics.

The OTC sector is expected to increase by a low CAGR between 2010 and 2015. Nevertheless, the sector is attractive and market concentration continues. In December 2009, sanofi-aventis agreed to acquire 100.0% of the outstanding shares of Chattem. The transaction will create the world’s fifth-largest consumer healthcare company. The modern generic sector is shaped by the Hatch Waxman legislation of 1984. As a result, generics are widely-used and well-accepted in the USA.

This is because generics are usually far cheaper than branded drugs, with the advent of generic competition leading to rapid price falls. The sector is expected to increase by a moderate CAGR between 2010 and 2015. The leading player is the Israeli company Teva Pharmaceuticals but competition is increasing; Watson completed the acquisition of Arrow in December 2009.

Consistent with trends of the past several years, the next five are expected to reflect a significant imbalance between new product introductions and patent losses. This is the primary factor limiting global pharmaceutical market growth to the mid-single digits through 2013. During the next five years, products that currently generate an unprecedented $137 billion in sales are expected to face generic competition, including Lipitor®, Plavix®, and Seretide®. At the same time, new products that will enable innovative approaches for treating patients suffering from diseases such as osteoporosis, respiratory ailments, thrombosis, multiple sclerosis and cancer are not expected to generate the same magnitude of sales as products losing patent protection.

GARAN S.K is welcome you to enjoy our benefit prices and over 18 years of experience in the pharmaceutical worldwide market, in API, BULL SUPPLAY, FINISH MEDICATION, all under one

Reliable and professional pharmaceutical company GARAN S.K.

I am a manager of medical device company. What could I get my sales reps for a Christmas gift?

Monday, August 30th, 2010

Nanotechnology In Healthcare: Market Outlook For Applications, Tools And Materials, And 40 Company Profiles-Aarkstore Enterprise

Wednesday, August 11th, 2010

This report covers different regional application markets, while evaluating them over the next five years. It provides information about the largest regional markets and factors influencing them, while defining the opportunities they present.

Key features of this report

• •Provides an analysis of market data (revenues) of healthcare nanotechnology applications in North America, Europe, Asia and Rest of World that includes Middle East, Africa, Russia, Latin America and Australia.
• Studies key market drivers and restraints for the main market and evaluation of respective sub segments with respect to market dynamics.
• Discusses drug delivery and formulations, biocompatible implants, regenerative medicine and wound care and diagnostics under the applications market along with related sub segments.

Scope of this report

• Understanding the existing and emerging applications of healthcare nanotechnology and their relative and forecast market sizes
• Understanding the product/technological developments on which the companies are focusing for their growth.
• Understanding the different nanotechnology based tools and their importance in the development of new products and applications

Key Market Issues

• Nanotechnology initiatives by developing countries are helping in the development of new products and applications.
• The delay in commercialization due to strict regulations and manufacturing difficulties is inhibiting product reach.
• Stability of nanoparticles inside the biological tissues is an important issue to be considered to reduce contamination by drugs.
• The development of biodegradable nanostructures will be a growth driver in future since they eliminate the issue of excretion.

Key findings from this report

• The healthcare nanotechnology market growth is largest in North America, at $4.75bn in 2009, followed by Europe at $3.65.
• The nanotechnology drug delivery market is expected to grow at a CAGR of 21.7% for the period 2009-14, to reach almost $16bn by 2014.
• Biocompatible implants and coatings and diagnostics comprise some of the major applications which are estimated to experience high growth between 2009 and 2014, 42% and 21.8% respectively.

Key questions answered

• What are the important healthcare nanotechnology markets and their growth over the period 2009-14?
• What are the major applications that have emerged in different areas such as drug formulations and delivery, biocompatible implants and coatings, regenerative medicines and wound care and diagnostics?
• In which areas are the companies focusing while forming strategic alliances with other industry players?

Table of Contents
Nanotechnology in Healthcare
Executive summary 16
Market overview 16
Healthcare nanotechnology market dynamics 16
Nanomaterials & nanotools for the healthcare market 17
Healthcare nanotechnology application market 18
Company profiles 19
Chapter 1 Market overview 22
Summary 22
Introduction 23
Market definition 23
Healthcare nanotechnology business processes 24
Healthcare nanotechnology applications 24
Healthcare nanotechnology application prospects 25
Opportunity matrix 26
Challenge matrix 28
Patent analysis 29
Chapter 2 Healthcare nanotechnology market dynamics 34
Summary 34
Introduction 35
Regional markets 36
North America 37
Europe 38
Asia 38
RoW 39
Competitive landscape 39
R&D activities by applications 41
New product launches 42
Collaborations & agreements 43
Market drivers 56
Nanotechnology research initiatives in developing nations 56
Innovations are increasing 56
Reduced toxicity 56
Market inhibitors 57
Delay in commercialization 57
Stability and other issues 57
Need for particle evaluation 57
Chapter 3 Nanomaterials & nanotools for the healthcare market 60
Summary 60
Introduction 61
Nanomaterials 61
Nanocapsules 61
Drivers 61
Inhibitors 62
Opportunities 62
Nanoporous materials 63
Drivers 63
Opportunities 63
Quantum dots 63
Drivers 64
Inhibitors 64
Opportunities 64
Nanotubes 65
Drivers 65
Nanowires 65
Drivers 66
Inhibitors 66
Opportunities 66
Dendrimers 67
Drivers 67
Opportunities 68
Monoclonal antibodies 68
Drivers 68
Inhibitors 69
Opportunities 69
Nanocomposites 69
Fullerenes 70
Nanofilms 70
Drivers 71
Inhibitors 71
Opportunities 71
Nanotools 72
Nanoarrays 72
Drivers 72
Inhibitors 73
Opportunities 73
Nanobiochip 74
Drivers 74
Opportunities 75
Nanolithography arrays 75
Drivers 75
Inhibitors 76
Opportunities 76
Computer-assisted drug discovery 77
Nanomass spectrometry 77
Drivers 77
Inhibitors 78
Opportunities 78
Congruent Force Intermolecular Test (nanotype) C-FIT 78
Chapter 4 Healthcare nanotechnology application market 82
Summary 82
Introduction 83
Drug formulation and delivery 83
Formulation 84
Drivers 85
Inhibitors 86
Opportunities 86
Fluorescently encoded microparticles 86
Nanoparticulate formulation/systems 88
Fluoropolymers as material platforms for drug therapy 88
DNA nanoparticle technology to produce DNA drugs 89
Drug profiling using smart materials 90
Supercritical fluids and water based nanomaterials 91
Dendrimer nanotechnology products 92
Potential healthcare nanotechnology drug formulation application 93
Drug delivery 93
Drivers 94
Inhibitors 95
Opportunities 95
Nanoencapsulation using nano-device platform 96
Smart materials for encapsulation 97
Antimicrobial nanoencapsulation 98
Nanoscale cochlear drug delivery 99
Drug delivery using nanoparticles 99
Nanocrystals for drug delivery 102
Drug delivery coatings 103
Nanopores 103
Nanocomposites 104
Nanotransponders 105
Potential applications of healthcare nanotechnology drug delivery 105
Biocompatible implants and coatings 106
Drivers 108
Nanofibers fight immune response 108
Improvement in biocompatibility 108
Optimized coatings 108
Improvement in dental implants 108
Inhibitors 108
Improvement of implant depends upon coatings 108
Possibility of mass poisoning 109
Opportunities 109
Improved brain implants 109
Improvement in process for better coatings 109
Helpful in orthopedic devices 109
Surface modification 109
Device coating 110
Drivers 112
Inhibitors 112
Opportunities 112
Sol-gel coatings 113
Biocompatible nanocoatings 113
Nanoscale plasma coating 113
Light-activated antimicrobials 113
Silver nanoparticles 114
Hydrophobic coatings 114
Multifunctional coatings 114
Anti-fouling nanocoatings 114
Passive hydroxyapatite coating 115
Other protective coatings 115
Implants 116
Drivers 116
Opportunities 117
Potential biocompatible implants applications 117
Life support devices using novel biocompatible polymers 117
Stimulation electrodes using nanotechnology 117
Noninvasive killing of cancer cells using localized heat 118
Artificial vascular grafts 118
Bone graft substitutes 118
Regenerative medicine and wound care 118
Regenerative medicine/tissue engineering 119
Drivers 120
Inhibitors 121
Opportunities 121
Potential applications of regenerative medicines 123
Wound care 124
Drivers 124
Opportunities 125
Nanosilver gels 125
Nanogold gels 125
Diagnostics 126
Drivers 127
Improved bioassays 127
Earlier diagnosis and effective monitoring 127
Opportunities 127
Treatment of ovarian cancer 127
Development of immunoassays 128
Quantum dots applications 128
Nanoemulsions in multimodal molecular imaging and targeted therapeutics 128
Nanoparticles for biochemical applications 129
Magnetic nanoparticles for medical diagnostic imaging 129
Encapsulation of radioactive nanoparticle 129
Genome sequencing 129
Nanobiosensors 130
Nanoarray biochips 130
Silicon-based chips/sensors for pH and pressure 130
Micro- and nano-replication for point-of-use analytical applications 131
Nanocells 131
Redox enzymes 131
Other potential diagnostics applications 132
Smart card diagnostics 132
Novel microfluidic technologies 132
Chapter 5 Company profiles 134
Summary 134
Abraxis BioScience, Inc. 135
Company overview 135
Products and services 135
Company strategy 136
Access Pharmaceuticals, Inc. 137
Company overview 137
Products and services 137
Company strategy 138
AstraZeneca 138
Company overview 138
Products and services 139
Company strategy 139
AMAG Pharmaceuticals, Inc. 139
Company overview 139
Products and services 140
Company strategy 140
Aphios Corp. 140
Company overview 141
Products and services 141
Company strategy 142
Asklepios Biopharmaceutical Inc. 142
Company overview 143
Products and services 143
Company strategy 143
Capsulution Nanoscience AG 144
Company overview 144
Products and services 144
Company strategy 144
ConvaTec 145
Company overview 145
Products and services 145
Company strategy 146
Debiotech 146
Company overview 146
Products and services 146
Company strategy 147
Do-Coop Technologies Ltd. 147
Company overview 147
Products and services 147
Company strategy 148
Elan Corp. 148
Company overview 148
Products and services 148
Company strategy 149
Ferro Corp. 149
Company overview 149
Products and services 150
Company strategy 150
Flamel Technologies 150
Company overview 151
Products and services 151
Company strategy 151
GE Global Research 152
Company overview 152
Company strategy 152
GfE Medizintechnik GmbH 153
Company overview 153
Products and services 153
Company strategy 154
HemCon Medical Technologies, Inc. 154
Company overview 154
Company strategy 155
iCeutica Inc 155
Company overview 155
Products and services 156
Company strategy 156
Liquidia Technologies 157
Company overview 157
Company strategy 157
Luna Innovations Inc. 158
Company overview 158
Products and services 158
Company strategy 159
MagForce Nanotechnologies AG 159
Company overview 160
Products and services 160
Company strategy 161
Merck KGaA 161
Company overview 161
Products and services 162
Company strategy 162
MIV Therapeutics Inc 162
Company overview 163
Products and services 163
Company strategy 163
Nanomix 163
Company overview 164
Products and services 164
Company strategy 164
Nano Interface Technology, Inc 165
Company overview 165
Products and services 165
Company strategy 165
NanoCarrier Co., Ltd. 165
Company overview 166
Products and services 166
Company strategy 166
NanoDel Technologies 167
Company overview 167
Products and services 167
Company strategy 167
NanoHorizons Inc. 168
Company overview 168
Products and services 168
Company strategy 168
Nanoprobes, Inc. 169
Company overview 169
Products and services 169
Company strategy 169
Nanospectra Biosciences Inc. 170
Company overview 170
Products and services 170
Company strategy 170
Nanosphere, Inc. 171
Company overview 171
Products and services 171
Company strategy 172
Novartis AG 172
Company overview 173
Products and services 173
Company strategy 173
Pfizer 173
Company overview 173
Company strategy 174
PharmaSol GmbH 174
Company overview 174
Products and services 174
Company strategy 175
Pioneer Surgical Technology 175
Company overview 175
Products and services 175
Company strategy 176
pSivida 176
Company overview 176
Products and services 176
Company strategy 176
F. Hoffmann–La Roche Ltd. 177
Company overview 177
Products and services 177
Company strategy 177
Siemens Medical Solutions 178
Company overview 178
Products and services 179
Company strategy 179
Smith & Nephew 179
Company overview 179
Products and services 180
Company strategy 180
Starpharma Holdings Ltd. 181
Company overview 181
Products and services 181
Company strategy 182
T2 Biosystems Inc. 183
Company overview 183
Company strategy 183
Appendix 184
Patents 184
Glossary 218

List of Figures
Figure 1.1: Global healthcare nanotechnology market 23
Figure 1.2: Geographical patent share, 2003-08 30
Figure 1.3: Number of patents by region, 2003-09 30
Figure 1.4: Comparison of patent trends, 2004 vs 2009 31
Figure 2.5: Developmental strategies by major players, January 2007–November 2009 40
Figure 2.6: R&D activities by applications, Jan 2007–Nov 2009 41
Figure 2.7: New product launches, Jan 2007–Nov 2009 42
Figure 2.8: Collaborations & agreements by applications, Jan 2007–Nov2009 43
Figure 2.9: Relative importance of features of healthcare nanotechnology 58

List of Tables
Table 2.1: Global healthcare nanotech market, by geography ($m), 2007-14 37
Table 2.2: Mergers & acquisitions in healthcare nanotech market, 2007–09 44
Table 2.3: New product launches in healthcare nanotech market, 2007–09 45
Table 2.4: New product launches in healthcare nanotech market, 2007–09 (ctd) 46
Table 2.5: R&D in healthcare nanotech market, 2007–09 47
Table 2.6: R&D in healthcare nanotech market, 2007–09 (ctd 1) 48
Table 2.7: R&D in healthcare nanotech market, 2007–09 (ctd 2) 49
Table 2.8: R&D in healthcare nanotech market, 2007–09 (ctd 3) 50
Table 2.9: R&D in healthcare nanotech market, 2007–09 (ctd 4) 51
Table 2.10: R&D in healthcare nanotech market, 2007–09 (ctd 5) 52
Table 2.11: R&D in healthcare nanotech market, 2007–09 (ctd 6) 53
Table 2.12: Collaborations & agreements in healthcare nanotech market, 2007–09 54
Table 2.13: Collaborations & agreements in healthcare nanotech market, 2007–09 (ctd) 55
Table 4.14: Global healthcare nanotech drug formulation and delivery market, by product ($m), 2007–14 83
Table 4.15: Global healthcare nanotech drug formulation and delivery market, by geography ($m), 2007–14 84
Table 4.16: Global healthcare nanotechnology drug formulation market, by product ($m), 2007–14 85
Table 4.17: Global healthcare nanotech fluorescently encoded microparticles market, by geography ($m), 2007–14 87
Table 4.18: Global healthcare nanotech nanoparticulate formulation/systems market, by geography ($m), 2007–14 88
Table 4.19: Global healthcare nanotech fluoropolymers material platforms for drug therapy market, by geography ($m), 2007–14 89
Table 4.20: Global healthcare DNA nanoparticle technology to produce DNA drugs market, by geography ($m), 2007-14 90
Table 4.21: Global healthcare nanotech drug profiling using smart materials market, by geography ($m), 2007-14 91
Table 4.22: Global healthcare nanotech supercritical fluids and water based nanomaterials market, by geography ($m), 2007-14 91
Table 4.23: Global dendrimer nanotech products market by geography ($m), 2007-14 92
Table 4.24: Global healthcare nanotech drug delivery market by product ($m), 2007-14 94
Table 4.25: Global healthcare nanoencapsulation using nano-device platform market, by product ($m), 2007-14 96
Table 4.26: Global healthcare nanoencapsulation using nano-device platform market, by geography ($m), 2007-14 97
Table 4.27: Global market for smart materials encapsulating pharmaceuticals, by geography ($m), 2007-14 98
Table 4.28: Global healthcare nanotech antimicrobial nanoencapsulation, by geography ($m), 2007-14 98
Table 4.29: Global healthcare nanotech nanoscale cochlear drug delivery, by geography ($m), 2007-14 99
Table 4.30: Global healthcare nanotech drug delivery using nanoparticles market, by product ($m), 2007-14 100
Table 4.31: Global healthcare nanotech drug delivery using nanoparticles market, by geography ($m), 2007-14 100
Table 4.32: Global drug delivery using nanocrystals market, by geography ($m), 2007-14 102
Table 4.33: Global healthcare nanotech drug delivery coatings market, by geography ($m), 2007- 14 103
Table 4.34: Global healthcare nanopores market, by geography ($m), 2007-14 104
Table 4.35: Global healthcare nanocomposites market, by geography ($m), 2007-14 104
Table 4.36: Global healthcare nanotech nanotransponder market, by geography ($m), 2007-14 105
Table 4.37: Global healthcare nanotech biocompatible implants and coatings market, by products ($m), 2007-14 107
Table 4.38: Global healthcare nanotech biocompatible implants and coatings market, by geography ($m), 2007-14 107
Table 4.39: Global healthcare nanotech surface modification market, by geography ($m), 2007-14 110
Table 4.40: Global healthcare nanotech device coating market, by products ($m), 2007-14 111
Table 4.41: Global healthcare nanotech device coating market, by geography ($m), 2007-14 111
Table 4.42: Global healthcare nanotech implants market, by geography ($m), 2007-14 116
Table 4.43: Global healthcare nanotech regenerative medicine and wound care market, by products
($m), 2007-14 119
Table 4.44: Global healthcare nanotech regenerative medicine market, by product ($m), 2007-14 120
Table 4.45: Global healthcare nanotech wound care market, by products ($m), 2007-14 124
Table 4.46: Global healthcare nanotech diagnostics market, by products ($m), 2007-14 126
Table 4.47: Global healthcare nanotech diagnostics market, by geography ($m), 2007-14 127
Table 0.48: US patents 184
Table 0.49: US patents (ctd 1) 185
Table 0.50: US patents (ctd 2) 186
Table 0.51: US patents (ctd 3) 187
Table 0.52: US patents (ctd 4) 188
Table 0.53: US patents (ctd 5) 189
Table 0.54: US patents (ctd 6) 190
Table 0.55: US patents (ctd 7) 191
Table 0.56: US patents (ctd 8) 192
Table 0.57: US patents (ctd 9) 193
Table 0.58: US patents (ctd 10) 194
Table 0.59: US patents (ctd 11) 195
Table 0.60: US patents (ctd 12) 196
Table 0.61: US patents (ctd 13) 197
Table 0.62: US patents (ctd 14) 198
Table 0.63: US patents (ctd 15) 199
Table 0.64: US patents (ctd 16) 200
Table 0.65: US patents (ctd 17) 201
Table 0.66: US patents (ctd 18) 202
Table 0.67: US patents (ctd 19) 203
Table 0.68: Europe patents 204
Table 0.69: Europe patents (ctd 1) 205
Table 0.70: Europe patents (ctd 2) 206
Table 0.71: Europe patents (ctd 3) 207
Table 0.72: Europe patents (ctd 4) 208
Table 0.73: Europe patents (ctd 5) 209
Table 0.74: Europe patents (ctd 6) 210
Table 0.75: Europe patents (ctd 7) 211
Table 0.76: Europe patents (ctd 8) 212
Table 0.77: Europe patents (ctd 9) 213
Table 0.78: Europe patents (ctd 10) 214
Table 0.79: Europe patents (ctd 11) 215
Table 0.80: Japan patents 216
Table 0.81: Japan patents (ctd 1) 217
 
For More information please contact :

  
http://www.aarkstore.com/reports/Nanotechnology-in-Healthcare-Market-outlook-for-applications-tools-and-materials-and-40-company-profiles-38032.html 

 

How do I get a medical device company to hire me?

Wednesday, August 4th, 2010

The Stock Wizards Reviews Medical Marijuana Company Cannabis Science (CBIS)

Thursday, July 29th, 2010

Boca Raton, FL- TheStockWizards.net, a Top Penny Stock newsletter presents stocks that have impact news and positive technical charting indicators on the OTC BB: and Pink Sheet markets. In addition to our newsletter, The Stock Wizards is quickly becoming the fastest growing network destination for Small-Cap, Micro-Cap & Penny Stocks. With our over 30 years combined experience; our team of research analyst pride themselves on small cap companies that are diamonds in the ruff.

 

At The Stock Wizards, we analyze daily market activity and provide our members with our technical outlook, winning stock picks, a weekly top ten list, and daily trading tips from the Traders Corner section of our website.  We follow certain patterns and bring you break out alerts, volume spikes, breaking news, upward trends, mergers and more.  We do all the research for you and send it straight to your inbox.

 

After researching this company, The Stock Wizards was shocked to learn of the many uses of medical cannabis, often referred to as medical marijuana.

 

The product is medical cannabis – a term which encompasses a wide variety of products, ranging from plants grown by patients for their own use to pharmaceutical products developed from one or more of the cannabinoid compounds found in the whole cannabis plant.

 

This is an exciting time for cannabinoid research. Cannabinoids are the (psycho) active ingredients in cannabis. The best-known cannabinoid is THC, tetrahydrocannabinol. THC is the magic ingredient that causes one to feel high. Cannabinoids act as a bio regulatory mechanism for most life processes, which explains why medical cannabis has been recommended as a treatment for many diseases and ailments in anecdotal reports and scientific literature. Some of these ailments include: Pain, arthritic conditions, migraine headaches, anxiety, epileptic seizures, insomnia, loss of appetite, GERD (chronic heartburn), nausea, glaucoma, AIDS wasting syndrome, depression, bipolar disorder (particularly depression-manic-normal), multiple sclerosis, menstrual cramps, Parkinson’s, trigeminal neuralgia (tic douloureux), high blood pressure, irritable bowel syndrome, and bladder incontinence.

 

CBIS Technical Outlook:

Medical marijuana has been a hot topic on Capitol Hill. CBIS is forming a very nice double bottom right at the bottom of the range, which makes this a very low risk trade. A weekly close above the 50-day moving average of .18 cents should get the momentum traders attention. Minor resistance .20, weekly support .10. We are watching for volume and news for indication of a breakout.  Any news out of Capitol Hill on this subject matter and this stock will explode immediately. If you’re building a list of Medical Marijuana stocks, put this at the top. With a market cap of only 8 million there is plenty of upside here.

 

http://cannabisscience.com

 

Millions of people are suffering needlessly because they cannot get access to medical cannabis (medical marijuana). CBIS wants to provide them with FDA approved cannabis medicines that are both safer and in many cases more effective than those currently available.

 

Cannabis Science – CBIS is dedicated to working with Federal, State, and Local regulatory agencies as well as entities such as the FDA and Health Canada in

order to not only ensure top of the line products for MMJ patients at a state level, but

also to bring new, FDA approved cannabis based pharmaceuticals to market that could eventually be covered under healthcare.

 

 

CBIS is rapidly expanding in five divisions:

 

1. Horticulture Division — Pharmaceutical Grade Medical Cannabis Grown Under Stringent Quality Controls.

 

2. Analytical Labs — State Of The Art Facilities For Developing Cannabis Based Extracts and Pharmaceutical Grade Drugs.

 

3. Manufacturing — Cutting Edge Facilities For Creating Oral and Topical Medications For Various Ailments.

 

4. Clinical Trials — Initial Clinical Trials for FDA Approval Will Target Veterans Suffering From Chronic Pain and PTSD.

 

5. Distribution — In State Dispensaries Today, National Pharmacies Tomorrow.

Forward-Looking Statement: This press release includes “forward-looking statements” within the meaning of the federal securities laws, commonly identified by such terms as “believes,” “looking ahead,” “anticipates,” “estimates” and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company’s projections and expectations are disclosed in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

 

The Stock Wizards has purchased 1.5 million shares of Cannabis Science (CBIS) from a third party at a discount to the market. For details please see our disclaimers and disclosures. Full Discloser, Disclaimers

 

TheStockWizards.net is not a registered investment advisers or broker/dealer. TheStockWizards.net makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk.

for more info visit http://www.stockwizards.net

Published by blogerzoom

Part 2: Keys to the Successful Development of Our Medical Device Company

Tuesday, July 13th, 2010


Part 2: Keys to the Successful Development of Our Medical Device Company Ken Moore, TENET Medical Engineering Inc. ACAMP Seminar: Health & Medical 2009 www.acamp.ca

Which qualities should a company seek in a medical device consulting firm?

Wednesday, April 7th, 2010

Dna Sequencing In Drug Discovery: Market Outlook For Applications, Tools And Services, And 40 Company Profiles -Aarkstore Enterprise

Wednesday, March 31st, 2010

Advanced technological developments in microarrays, bioinformatics and similar tools have increased the scope of applications and services.

This report covers regional markets, products and services while evaluating them over the next five years, and profiles almost 40 companies involved in the DNA sequencing market.

Key features of this report

It analyzes the market data ( revenues ) of DNA sequencing tools and services in North America, Europe, Asia and rest of the world that includes Middle East, Africa, Russia, Latin America and Australia.

Key market drivers and restraints for the parent segments and evaluation of respective sub segments with respect to market dynamics.

Covers microarray, DNA sequencing kits, chromatography, mass spectrometry, DNA amplification and many others within the tools market along with their sub segments. The services market includes high throughput sequencing , shot gun sequencing , re-sequencing, sample process and primer walking, single pass analysis and bacterial identification.

Scope of this report

Understand the emerging technologies and the growth associated for evaluation of potential of the type of products and services.

Understanding the product developments on which companies are focusing to evaluate new technological trends.

For evaluation of growth prospective for DNA sequencing applications and determining lucrative markets.

Key Market Issues

Funding from public institutes is encouraging market players to focus on the development of the DNA sequencing technology.

The withdrawal of certain drugs from the market due to their lack of efficacy among the worldwide patient population has created a need to address variations in diseases and drug responses on an individual basis.

Next generation sequencing may hinder the growth of the market for first-generation DNA sequencing technology especially in the drug discovery and development sector.

Key findings from this report

The DNA sequencing market growth is highest in the Asian and North American region, with Europe having the second largest market.

North America constitutes the major market share with next-generation sequencing attracting the new participants in the region.

The existing market participants are strategically positioning their DNA sequencing technologies by differentiating the specificity of the type of their tools and services.

Agilent Technologies, CLC Bio, and Life Technologies Corporation are some of the major DNA sequencing companies engaged in collaborative partnerships in the past couple of years.

Key questions answered

What are the important DNA sequencing markets and their growth over the period 2009-14?

What are the major technologies and services that have emerged in different areas such as microarray, PCR, re-sequencing, high throughput sequencing?

In which areas are the companies focusing while forming strategic alliances with other market players?

What is the current potential of DNA sequencing applications with respect to drug development and discovery?
 
 
  Table of Contents : 
DNA Sequencing in Drug Discovery
Executive summary
Market overview
Market dynamics
Global DNA sequencing tools & services market
Company profiles
Chapter 1 Market overview
Summary
Evolution of DNA sequencing
DNA sequencing and drug discovery
Defining the market
Need for more reliable and compatible tools
High throughput and next-generation sequencing – attractive growth factors
DNA sequencing tools dominate the market
Protecting DNA sequencing technology
Applications of DNA sequencing
Drug development
Clinical trials
Whole genome testing
Toxicology prediction
Identification of drug resistance
Drug discovery
Chapter 2 Market dynamics
Summary
Introduction
Regional markets
North America
Europe
Asia
RoW
Competitive landscape
Recent agreements and collaborations
Recent launches
Market drivers
Funding from public institutes
NGS technologies
Patient profiling for genetic disorders
Development of personalized medicine
High productivity rates
Market restraints
Shift in sequencing market trends
Introduction of NGS technologies
Chapter 3 Global DNA sequencing tools & services market
Summary
DNA sequencing tools
Microarray
Biochip microarray
Gel array
Array design kit
Low and high density microarrays
Bioinformatics
Electrophoresis
Gel electrophoresis
Capillary electrophoresis
DNA sequencing kits
Consumables, chemicals, reagents and probes
DNA polymerase
Primers
Automated DNA sequencers
Chromatography
DNA amplification (PCR)
Mass spectrometry
Microscopy-based techniques
Electron microscopy
Atomic force microscopy
Microfluidics-enabled workstations
Barcode readers for DNA sample presentation
Computational chemistry and biology modeling
Spotters/arrayers
Centrifuge
Scanners
Thermal cyclers
Charge-coupled devices (CCDs)
Plates, strips and columns
DNA sequencing services
High throughput sequencing
Shotgun sequencing
Re-sequencing
Sample process and primer walking
Single pass analysis
Bacterial identification
Market drivers
Microarray technology is a powerful tool for high throughput screening
Increasing applications of microarrays
Increasing applications of bioinformatics in R&D
Technological breakthroughs generate need for efficient DNA sequencing
Genomics and drug discovery applications of automated sequencers
Diagnostic applications of automated sequencers
Applications in comparative research projects of automated sequencers
Developments in PCR technology
PCR is a reliable tool for multiple applications
Government initiative for funding
Market restraints
Limited scope of microarrays for pathogen enumeration
Time loss due to large number of laboratory specific variations for microarrays
Low cost next-generation technologies hinder growth of microarrays
Incompatibility issues of current bioinformatics tools
High cost of modifying supporting products
High cost and reliability issues of PCR technology
Chapter 4 Company profiles
Summary
454 Life Sciences
Company overview
Products and services
Company strategy
Other events
Affymetrix
Company overview
Product and services
Company strategy
Agilent Technologies
Company overview
Products and services
Company strategy
Beckman Coulter, Inc
Company overview
Products and services
Company strategy
Bio-Rad Laboratories
Company overview
Products and services
Company strategy
Caliper Life Sciences
Company overview
Products and services
Company strategy
CapitalBio Corp.
Company overview
Products and services
Company strategy
CombiMatrix Corp.
Company overview
Products and services
Company strategy
Commonwealth Biotechnologies, Inc
Company overview
Products and services
Company strategy
Complete Genomics, Inc
Company overview
Products and services
Company strategy
DNA Vision
Company overview
Products and services
Company strategy
Enzo Biochem, Inc
Company overview
Products and services
Company strategy
EPICENTRE Biotechnologies
Company overview
Products and services
Company strategy
Eurofins MWG Operon
Company overview
Products and services
Company strategy
GE Healthcare
Company overview
Products and services
Company strategy
Gen-Probe Life Sciences
Company overview
Products and services
Company strategy
GVK Biosciences (GVK BIO)
Company overview
Products and services
Company strategy
Helicos BioSciences Corp.
Company overview
Products and services
Company strategy
Illumina, Inc
Company overview
Products and services
Company strategy
Integrated DNA Technologies
Company overview
Products and services
Company strategy
Kapa Biosystems, Inc
Company overview
Products and services
Company strategy
Life Technologies Corp.
Company overview
Products and services
Company strategy
Microchip Biotechnologies, Inc
Company overview
Products and services
Company strategy
Nanogen, Inc
Company overview
Products and services
Company strategy
Ocimum Biosolutions Ltd.
Company overview
Products and services
Company strategy
Pacific Biosciences
Company overview
Company strategy
PamGene
Company overview
Products and services
Company strategy
Promega Corp.
Company overview
Products and services
Company strategy
QIAGEN
Company overview
Products and services
Company strategy
Sequenom
Company overview
Products and services
Company strategy
Shimadzu Biotech
Company overview
Products and services
Company strategy
Siemens Healthcare Diagnostics
Company overview
Products and services
Company strategy
Sigma-Aldrich
Company overview
Products and services
Company strategy
SoftGenetics, LLC.
Company overview
Products and services
Company strategy
Thermo Fisher Scientific, Inc
Company overview
Products and services
Company strategy
Third Wave Technologies, Inc
Company overview
Products and services
Company strategy
VisiGen Biotechnologies
Company overview
Products and services
Company strategy
ZS Genetics
Company overview
Products and services
Company strategy
Chapter 5 Appendix
Glossary
Patents
List of Figures
Figure 1.1: Developments in DNA sequencing
Figure 1.2: DNA sequencing in drug discovery and development
Figure 1.3: DNA sequencing and drug discovery market
Figure 1.4: Relative importance of features of DNA sequencing tools, 2009 versus 2014
Figure 1.5: DNA sequencing market drivers
Figure 1.6: DNA sequencing tools market dynamics
Figure 1.7: Patent analysis by technology, 2007 versus 2009
Figure 1.8: Patent analysis by geography, 2006 versus 2008
Figure 1.9: Patent applications (%) by competitors, 2004- Oct 09
Figure 2.10: Major segments of the global DNA sequencing market (%), 2008-09
Figure 2.11: Competitive landscape (%), 2008-09
List of Tables
Table 1.1: Global DNA sequencing market by tools and services ($m), 2007-14
Table 1.2: Global DNA sequencing applications market by applications ($m), 2007-14
Table 1.3: Global drug development market, by applications ($m), 2007-14
Table 1.4: Global drug discovery market, by applications ($m), 2007-14
Table 2.5: Global DNA sequencing market, by geography ($m), 2007-14
Table 2.6: Agreements and collaborations in the DNA sequencing market, 2008-09
Table 2.7: New product, technology & service launch in the DNA sequencing market, 2008-09
Table 2.8: New product, technology & service launch in the DNA sequencing market, 2008-09 (ctd1)
Table 2.9: New product, technology & service launch in the DNA sequencing market, 2008-09 (ctd2)
Table 2.10: New product, technology & service launch in the DNA sequencing market, 2008-09 (ctd3)
Table 3.11: Global DNA sequencing tools market, by geography ($m), 2007-14
Table 3.12: Global DNA sequencing tools market, by products ($m), 2007-14
Table 3.13: Global microarray market, by products ($m), 2007-14
Table 3.14: Global microarray market, by geography ($m), 2007-14
Table 3.15: Global biochip microarray market, by geography ($m), 2007-14
Table 3.16: Global gel array market, by geography ($m), 2007-14
Table 3.17: Global array design kit market, by geography ($m), 2007-14
Table 3.18: Global high and low density microarray market, by geography ($m), 2007-14
Table 3.19: Global bioinformatics market, by products ($m), 2007-14
Table 3.20: Global bioinformatics market, by geography ($m), 2007-14
Table 3.21: Global electrophoresis market, by products ($m), 2007-14
Table 3.22: Global electrophoresis market, by geography ($m), 2007-14
Table 3.23: Global gel electrophoresis market, by geography ($m), 2007-14
Table 3.24: Global capillary electrophoresis market, by geography ($m), 2007-14
Table 3.25: Global DNA sequencing kits and others market, by geography ($m), 2007-14
Table 3.26: Global consumables, chemicals, reagents and probes market, by products ($m), 2007-14
Table 3.27: Global consumables, chemicals, reagents and probes market, by geography ($m), 2007-14
Table 3.28: Global DNA polymerase market, by geography ($m), 2007-14
Table 3.29: Global primers market, by geography ($m), 2007-14
Table 3.30: Global automated DNA sequencers market, by geography ($m), 2007-14
Table 3.31: Global chromatography market, by geography ($m), 2007-14
Table 3.32: Global DNA amplification (PCR) market, by geography ($m), 2007-14
Table 3.33: Global mass spectrometry market, by geography ($m), 2007-14
Table 3.34: Global microscopy-based techniques market, by products ($m), 2007-14
Table 3.35: Global microscopy-based techniques market, by geography, ($m), 2007-14
Table 3.36: Global electron microscopy market, by geography ($m), 2007-14
Table 3.37: Global AFM market, by geography ($m), 2007-14
Table 3.38: Global microfluidics-enabled workstations market, by geography ($m), 2007-14
Table 3.39: Global barcode readers market for DNA sample presentation, by geography ($m), 2007-14
Table 3.40: Global computational chemistry and biology modeling market, by geography ($m), 2007-14
Table 3.41: Global spotters/arrayers market, by geography ($m), 2007-14
Table 3.42: Global centrifuge market, by geography ($m), 2007-14
Table 3.43: Global scanners market, by geography ($m), 2007-14
Table 3.44: Global thermal cycler market, by geography ($m), 2007-14
Table 3.45: Global charge-coupled devices market, by geography ($m), 2007-14
Table 3.46: Global plates, strips and columns market by geography ($m), 2007-14
Table 3.47: Global DNA sequencing services market by products ($m), 2007-14
Table 3.48: Global DNA sequencing services market, by geography ($m), 2007-14
Table 3.49: Global high throughput sequencing market, by geography ($m), 2007-14
Table 3.50: Global shotgun sequencing market, by geography ($m), 2007-14
Table 3.51: Global re-sequencing market, by geography ($m), 2007-14
Table 3.52: Global sample process and primer walking market by geography ($m), 2007-14
Table 3.53: Global single pass analysis market, by geography ($m), 2007-14
Table 3.54: Global bacterial identification market, by geography ($m), 2007-14
Table 5.55: US patents
Table 5.56: US patents (ctd 1)
Table 5.57: US patents (ctd 2)
Table 5.58: US patents (ctd 3)
Table 5.59: US patents (ctd 4)
Table 5.60: US patents (ctd 5)
Table 5.61: US patents (ctd 6)
Table 5.62: US patents (ctd 7)
Table 5.63: US patents (ctd 8)
Table 5.64: European patents
Table 5.65: European patents (ctd 1)
Table 5.66: European patents (ctd 2)
Table 5.67: European patents (ctd 3)
Table 5.68: European patents (ctd 4)
Table 5.69: European patents (ctd 5)
Table 5.70: European patents (ctd 6)
Table 5.71: European patents (ctd 7)
Table 5.72: European patents (ctd 7)
Table 5.73: European patents (ctd 8)
Table 5.74: European patents (ctd 9)
Table 5.75: European patents (ctd 10)
Table 5.76: European patents (ctd 11)
Table 5.77: Japanese patents
Table 5.78: Japanese patents (ctd 2)
Table 5.79: Japanese patents (ctd 3)
Table 5.80: Japanese patents (ctd 4) 
 

For More information please contact :

http://www.aarkstore.com/reports/DNA-Sequencing-In-Drug-Discovery-Market-outlook-for-applications-tools-and-services-and-40-company-profiles-35714.html

What logo/design ideas would you make for a highly innovative medical device company…?

Wednesday, March 17th, 2010

…That focuses on providing physicians new and promising therapy for managing compression fractures of the spine while providing patients with much needed pain relief.

What sort of design would you do, please describe in detail. Thanks

Is it is good time to start a medical device startup? What is the best location for such a startup company?

Sunday, March 14th, 2010